Clinical trial
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
NCT00229697 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00229697 |
|---|---|
| Title | Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study |
| Official title | A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Gefitinib, Tamoxifen |
| Enrollment | 317 |
| Start date | Oct 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Jun 1, 2015 |
| First posted | Sep 30, 2005 |
| Last update posted | Oct 5, 2015 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Germany, South Africa, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: